Acucort AB (NV5)

Overview

AcuCort AB (publ) is a pharmaceutical company based in Lund, Sweden, which was founded in 2006. The company specializes in the development and commercialization of innovative products in the field of medicine, specifically focusing on the utilization of glucocorticoid dexamethasone films. AcuCort's efforts are directed towards addressing acute allergic conditions, aiming to provide efficient and convenient treatments. The company leverages its expertise in pharmaceutical technology to create solutions that improve patient outcomes and enhance the quality of care for individuals experiencing severe allergic reactions and other acute conditions.

Products and Services

• Zeqmelit

Zeqmelit represents AcuCort AB's flagship product, designed as a cutting-edge solution for several acute medical conditions. This medicine utilizes a glucocorticoid dexamethasone film, offering a novel method of delivering this potent anti-inflammatory and immune suppressant agent. Zeqmelit is primarily used for treating severe and acute allergic reactions, providing rapid relief from symptoms. Additionally, it serves an important role in the treatment of croup in children, a respiratory condition that can cause significant distress and breathing difficulties. For patients undergoing chemotherapy, Zeqmelit offers an effective way to manage chemotherapy-induced nausea and vomiting, thereby improving patient comfort and adherence to cancer treatment regimens. In the context of the global COVID-19 pandemic, Zeqmelit has also been identified as a beneficial treatment option for patients who require supplemental oxygen treatment, showcasing the versatility and potential of AcuCort's pharmaceutical innovation.